SCHEMBL6109043

SCHEMBL6109043

Nc1ncnc2c1c(I)nn2[C@H]1CC[C@@H](O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 1.00
SRC P12931 4/20 1.00
JAK2 O60674 3/20 1.00
RET P07949 3/20 1.00
DYRK3 O43781 2/20 1.00
CDK1 P06493 2/20 1.00
ROS1 P08922 2/20 1.00
RPS6KB1 P23443 2/20 1.00
CDK2 P24941 2/20 1.00
CSNK1A1 P48729 2/20 1.00
CSNK1D P48730 2/20 1.00
CLK2 P49760 2/20 1.00
IRAK1 P51617 2/20 1.00
CDK5 Q00535 2/20 1.00
DYRK1A Q13627 2/20 1.00
NTRK3 Q16288 2/20 1.00
SLK Q9H2G2 2/20 1.00
CLK4 Q9HAZ1 2/20 1.00
CDC7 O00311 1/20 1.00
PLK4 O00444 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6109045 1.00 KDR (1.00) KDRSRCJAK2RETDYRK3
SCHEMBL6109435 1.00 KDR (1.00) KDRSRCJAK2RETDYRK3
SCHEMBL22243320 0.93 KDR (0.87) KDRSRCJAK2RETDYRK3
SCHEMBL24096480 0.93 JAK2 (0.86) KDRSRCJAK2RETDYRK3
Bicarbonate SCHEMBL27088025 0.89 RET (0.80) KDRSRCJAK2RETDYRK3
SCHEMBL12422280 0.89 KDR (0.80) KDRSRCJAK2RETDYRK3
SCHEMBL4826083 0.87 KDR (0.78) KDRSRCJAK2RETDYRK3
SCHEMBL4826075 0.87 KDR (0.78) KDRSRCJAK2RETDYRK3
SCHEMBL17911543 0.87 KDR (0.78) KDRSRCJAK2RETDYRK3
SCHEMBL1318717 0.87 SRC (0.77) KDRSRCJAK2RETDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113710671-A Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药(上海)有限公司 2021-11-26 CN disclosed
EP-3912980-A1 CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR Minghui Pharmaceutical (Shanghai) Limited (CN) 2021-11-24 EP disclosed
CN-111454268-A Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药(上海)有限公司 2020-07-28 CN disclosed
WO-2020147798-A1 CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR 明慧医药(上海)有限公司 2020-07-23 WO disclosed
US-10266537-B2 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof St. Chuan University (CN) 2019-04-23 US disclosed
US-20170305920-A1 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF SI CHUAN UNIVERSITY (CN) 2017-10-26 US disclosed
US-20170305920-A1 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF SI CHUAN UNIVERSITY (CN) 2017-10-26 US disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 KDR 2441/4885SRC 116/4885JAK2 119/4885
US-20170305920-A1 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF DPYD, TYMP, WEE1 KDR 2340/4885SRC 1111/4885JAK2 307/4885
US-10266537-B2 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof DPYD, TYMP, WEE1 KDR 2340/4885SRC 1111/4885JAK2 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.